Welcome back to Norton Rose Fulbright’s global antitrust and competition webinar series, Competitive edge, hosted by Global Head of Antitrust and Competition, Robin Adelstein.

Join us for this upcoming session where we will examine the implications of the recent US$885 million Takeda Hatch-Waxman reverse payment verdict, which is the first of its kind to go to a jury following the Supreme Court’s decision in FTC v. Actavis. This decision marks a significant development at the intersection of antitrust and intellectual property (IP) law, with important consequences for life sciences companies navigating patent settlements, litigation strategy and regulatory scrutiny.

In this joint discussion, our antitrust and IP disputes lawyers will share practical perspectives on:

• What the Takeda verdict signals for “reverse payment” cases post-Actavis

• How courts and juries are evaluating pharmaceutical patent settlements

• Key takeaways for structuring and documenting agreements going forward

• The increasing convergence of antitrust and IP risk in the life sciences sector